journal article·2026-08Open access

P2-engineered exosomes encapsulating curcumin alleviate cognitive decline in AD-like mice by improving microglia-related neuropathology

Xiaobin Huang, Guobo Xu, Yanhua Zhou, Dong Wang, Lili Ai, Hongmei Liu, Anran Fan, Likun Wang, Peng Zhang

Abstract

-Cur significantly suppressed the polarization of BV2 cells toward the M1 phenotype, as well as the secretion of pro-inflammatory cytokines. Finally, we also validated the excellent therapeutic potential of this technology in the 5xFAD mouse model. In conclusion, in this study, we for the first time constructed engineered exosomes that can specifically bind to the NCAM protein on microglia to achieve precise delivery of curcumin by expressing the P2 peptide on their surface, exerting beneficial effects in AD treatment without causing significant adverse effects. This strategy may offer a non-invasive and innovative therapeutic method for the management of brain inflammation-related diseases.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Curcumin's Biomedical Applications · Neuroinflammation and Neurodegeneration Mechanisms · Alzheimer's disease research and treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (54)

Show source-provided references
1. Disease-Modifying therapies for Alzheimer's Disease: more questions than answers10.1007/s13311-022-01201-2 ↗
2. Microglia polarization in alzheimer's disease: mechanisms and a potential therapeutic target10.3389/fnagi.2021.772717 ↗
3. Astrocytic and microglial cells as the modulators of neuroinflammation in Alzheimer's disease10.1186/s12974-022-02565-0 ↗
4. Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer's disease10.1038/nature25158 ↗
5. Glial cells in the early stages of neurodegeneration: pathogenesis and therapeutic targets10.3390/ijms262411995 ↗
6. Microglia function in the central nervous system during health and neurodegeneration10.1146/annurev-immunol-051116-052358 ↗
7. Microglia in Alzheimer's disease10.1083/jcb.201709069 ↗
8. The dual Nature of microglia in Alzheimer's Disease: a Microglia-Neuron Crosstalk Perspective10.1177/10738584211070273 ↗
9. Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques10.1038/ncomms7176 ↗
10. Sodium rutin ameliorates Alzheimer's disease-like pathology by enhancing microglial amyloid-β clearance10.1126/sciadv.aau6328 ↗
11. Cognitive enhancement and neuroprotective effects of OABL, a sesquiterpene lactone in 5xFAD Alzheimer's disease mice model10.1016/j.redox.2022.102229 ↗
12. Antiallergic drug desloratadine as a selective antagonist of 5HT(2A) receptor ameliorates pathology of Alzheimer's disease model mice by improving microglial dysfunction10.1111/acel.13286 ↗
13. Drug delivery to the central nervous system10.1038/s41578-021-00394-w ↗
14. Micro/nanosystems for controllable drug delivery to the brain
15. Exosomes─Nature's lipid nanoparticles, a rising star in drug delivery and diagnostics10.1021/acsnano.2c08774 ↗
16. Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis10.3390/cells8070727 ↗
17. Membrane vesicles as conveyors of immune responses10.1038/nri2567 ↗
18. Exosome for mRNA delivery: strategies and therapeutic applications10.1186/s12951-024-02634-x ↗
19. Mesenchymal stem cell-derived extracellular vesicles: challenges in clinical applications10.3389/fcell.2020.00149 ↗
20. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes10.1038/nbt.1807 ↗
21. Induction of neuronal differentiation by a peptide corresponding to the homophilic binding site of the second Ig module of the neural cell adhesion molecule10.1074/jbc.M109694200 ↗
22. Precise gene delivery systems with detachable albumin shell remodeling dysfunctional microglia by TREM2 for treatment of Alzheimer's disease10.1016/j.biomaterials.2021.121360 ↗
23. Curcuma Longa (turmeric): from traditional applications to modern plant medicine research hotspots10.1186/s13020-025-01115-z ↗
24. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes10.1038/mt.2010.105 ↗
25. Immunotherapy for Alzheimer's disease: targeting β-amyloid and beyond10.1186/s40035-022-00292-3 ↗
26. BACE-1 and γ-Secretase as therapeutic targets for Alzheimer's Disease10.3390/ph12010041 ↗
27. Review on Alzheimer's disease: inhibition of amyloid beta and tau tangle formation10.1016/j.ijbiomac.2020.11.192 ↗
28. Restoring amyloid-β42 and γ-secretase function in Alzheimer's disease10.1093/brain/awaf294 ↗
29. On the origin of Alzheimer's disease. Trials and tribulations of the amyloid hypothesis10.1016/j.arr.2013.10.001 ↗
30. Neuroinflammation in Alzheimer's disease: current evidence and future directions10.1016/j.jalz.2016.02.010 ↗
31. Role of neuroinflammation in neurodegeneration development10.1038/s41392-023-01486-5 ↗
32. Microglia mediated neuroinflammation in neurodegenerative diseases: a review on the cell signaling pathways involved in microglial activation10.1016/j.jneuroim.2023.578180 ↗
33. Microglial activation as a hallmark of neuroinflammation in Alzheimer's disease10.1007/s11011-025-01631-9 ↗
34. Microglia turnover with aging and in an Alzheimer's model via long-term in vivo single-cell imaging10.1038/nn.4631 ↗
35. Homeostatic microglia initially seed and activated microglia later reshape amyloid plaques in Alzheimer's Disease10.1038/s41467-024-54779-w ↗
36. Cordycepin improved neuronal synaptic plasticity through CREB-induced NGF upregulation driven by MG-M2 polarization: a microglia-neuron symphony in AD10.1016/j.biopha.2022.114054 ↗
37. The blood-brain barrier in neurodegenerative disease: a rhetorical perspective10.1111/j.1471-4159.2009.06319.x ↗
38. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain10.1038/mt.2011.164 ↗
39. Strategies for delivering therapeutics across the blood-brain barrier10.1038/s41573-021-00139-y ↗
40. Engineering precision nanoparticles for drug delivery10.1038/s41573-020-0090-8 ↗
41. Recent advances in extracellular vesicles for therapeutic cargo delivery10.1038/s12276-024-01201-6 ↗
42. Engineered exosomes: a promising drug delivery platform with therapeutic potential10.3389/fmolb.2025.1583992 ↗
43. Biomimetic nanovesicles as a dual gene delivery System for the synergistic gene therapy of alzheimer's disease10.1021/acsnano.3c13150 ↗
44. Angiopep-2-engineered extracellular vesicles derived from spinal cord injury-responsive brown adipose tissue for targeted neuroinflammation modulation10.1186/s12951-026-04163-1 ↗
45. Nanosystems for targeted drug Delivery: innovations and challenges in overcoming the Blood-Brain barrier for neurodegenerative disease and cancer therapy10.1016/j.ijpharm.2024.124800 ↗
46. Current strategies for brain drug delivery10.7150/thno.21254 ↗
47. Omnidirectional improvement of mitochondrial health in Alzheimer's disease by multi-targeting engineered activated neutrophil exosomes10.1016/j.jconrel.2024.10.033 ↗
48. Engineering exosomes for targeted drug delivery10.7150/thno.52570 ↗
49. Effects of P2, a peptide derived from a homophilic binding site in the neural cell adhesion molecule on learning and memory in rats10.1016/j.neuroscience.2007.08.008 ↗
50. NCAM-induced intracellular signaling revisited10.1002/jnr.21551 ↗
51. The NCAM-derived P2 peptide facilitates recovery of cognitive and motor function and ameliorates neuropathology following traumatic brain injury10.1111/j.1460-9568.2008.06245.x ↗
52. Neuroinflammation as a link in parkinson's and alzheimer's diseases: a systematic review and meta-analysis
53. Noteworthy perspectives on microglia in neuropsychiatric disorders10.1186/s12974-023-02901-y ↗
54. Stem cell-derived exosomes: a comprehensive review of biomedical applications, challenges, and future directions10.2147/IJN.S527137 ↗